title: Nivolumab: promising survival signal coupled with limited toxicity raises expectations.
authors.affiliation: National Cancer Institute, Bethesda, MD.
authors.forename: Geraldine
authors.initials: G
authors.lastname: O'Sullivan Coyne
authors.forename: Ravi A
authors.initials: RA
authors.lastname: Madan
authors.forename: James L
authors.initials: JL
authors.lastname: Gulley
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D000077594:Nivolumab; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab